Company Overview and News
MONTREAL, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Goldstar Minerals Inc. (“Goldstar” or the “Corporation”) (TSX-V: GDM) has begun receiving assays results from its most recent drilling campaign. In the normal course of quality assurance and quality control, assay results from some holes were found to be not reliable. On that basis, a significant number of samples will be assayed at another lab to understand the inconsistencies that have been found.
MONTRÉAL, QUÉBEC, May 22, 2018 (GLOBE NEWSWIRE) -- Goldstar Minerals Inc. (“Goldstar” or the “Company”) (TSX-V:GDM) is pleased to announce that the Company is putting the final touches on the targeting process and expects to soon begin its diamond drilling program on the Lake George Property, located in New Brunswick, Canada. Field crews are being mobilized and, once site preparation is completed, drilling is expected to begin in early June.
MONTRÉAL, May 17, 2018 (GLOBE NEWSWIRE) -- Goldstar Minerals Inc. (TSX-V:GDM) (“Goldstar” or the “Company”) is pleased to announce that the Company has granted 5,287,292 stock options to directors, officers and service providers exercisable at $0.10. These options vest immediately and have a five-year term. These options are subject to regulatory and shareholder approval.
MONTRÉAL, 09 mai 2018 (GLOBE NEWSWIRE) -- Société minière Goldstar - Goldstar Minerals Inc. (TSX‑V:GDM) (la “Société”) annonce la clôture de son placement de droits antérieurement annoncé. Aux termes de celui-ci, la Société émettra 14 006 548 actions ordinaires au prix de 0,05 $ l’action pour un produit brut total de 700 327,40 $.
MONTRÉAL, May 09, 2018 (GLOBE NEWSWIRE) -- Goldstar Minerals Inc. (TSX-V:GDM) (the “Company”) announces the closing of its previously announced rights offering (the “Offering”). Under the Offering, the Company will be issuing 14,006,548 common shares at $0.05 per share for aggregate gross proceeds of $700,327.40.
MONTRÉAL, April 11, 2018 (GLOBE NEWSWIRE) -- Goldstar Minerals Inc. (“Goldstar” or the “Company”) (TSX-V:GDM) is pleased to announce that the permitting is now complete as all private landowners have been consulted with respect to the upcoming drilling program on its Lake George Property, located in New Brunswick, Canada. The Company expects to begin its second phase diamond drill program in early June, focusing its efforts on the Coyote and WLF gold zones.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to TSXV:GDM / Goldstar Minerals Inc on message board site Silicon Investor.